# OnCo record mogamulizumab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/mogamulizumab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "mogamulizumab" ;
  schema:name "Mogamulizumab"@en ;
  schema:description "Mogamulizumab is an antibody that clears cancerous T cells from the blood in mycosis fungoides and Sézary syndrome, the leukaemic form of skin lymphoma."@en ;
  schema:url <https://onco.cc/drugs/mogamulizumab/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Mogamulizumab> ;
  owl:sameAs <http://www.wikidata.org/entity/Q6890447> ;
  schema:citation <https://doi.org/10.1016/S1470-2045(18)30379-6>, <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=mogamulizumab>, <https://doi.org/10.1016/S1470-2045(18)30379-6>, <https://doi.org/10.1038/ng.3415> ;
  onco:status "approved" ;
  onco:tag "gap-fill" ;
  onco:modality "Defucosylated anti-CCR4 monoclonal antibody" ;
  schema:alternateName "Poteligeo" ;
  onco:approval "JP 2012: Relapsed CCR4+ adult T-cell leukaemia/lymphoma; later PTCL/CTCL", "US 2018: Relapsed/refractory mycosis fungoides or Sézary syndrome after ≥1 systemic therapy", "EU 2018: MF/SS after ≥1 systemic therapy" ;
  onco:cancers <https://onco.cc/cancers/peripheral-t-cell-lymphoma/>, <https://onco.cc/cancers/cutaneous-t-cell-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/ccr4/> ;
  onco:companies <https://onco.cc/companies/kyowa-kirin/> ;
  onco:terms <https://onco.cc/terms/adcc/>, <https://onco.cc/terms/fc-effector/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-mavoric-mogamulizumab-lancet-oncol-2018/> .